Cincor Pharma, Inc. (CINC)

They are a clinical-stage biopharmaceutical company focused on developing their lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Despite the widespread availability of multiple antihypertensive agents, there remains a significant unmet medical need as more than half of the 108 million hypertensive patients in the US do not achieve blood pressure control. They are evaluating the efficacy and safety profile of CIN-107 as a potential treatment for the broader hypertensive population, including different subpopulations who have not achieved blood pressure control despite treatment, and are currently in two Phase 2 trials for different subpopulations. In addition to hypertension, they are developing CIN-107 for primary aldosteronism, or PA, and exploring its utility in ameliorating complications of chronic kidney disease, or CKD. Earlier this year, they initiated a Phase 2 trial of CIN-107 in patients with confirmed PA, and plan to initiate a Phase 2 trial in patients with CKD who have uncontrolled blood pressure in the first half of 2022.

Industry
Pharmaceutical Preparations

CEO	CFO
-

Employees	Founded
10	2018

Address: 200 Clarendon Street, 6th Floor Boston, Ma 02116

Telephone: (844) 531-1834

Web page: http://www.cincor.com

First Trade Date	1/7/2022
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the CINC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Morgan Stanley

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Morgan Stanley/ Jefferies/ Evercore ISI
CO-Managers
Oppenheimer & Co.